NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Kyndryl Holdings, Inc. (NYSE: KD) resulting from allegations that Kyndryl may have issued materially misleading business information to the investing public. So What: If you purchased Kyndryl securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

New York, New York--(Newsfile Corp. - February 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Integer Holdings Corporation (NYSE: ITGR) between July 25, 2024 and October 22, 2025, both dates inclusive (the "Class Period"), of the important February 9, 2026 lead plaintiff deadline.SO WHAT: If you purchased Integer common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a cont ...

New York, New York--(Newsfile Corp. - February 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of PennyMac Financial Services, Inc. (NYSE: PFSI) resulting from allegations that PennyMac may have issued materially misleading business information to the investing public.SO WHAT: If you purchased PennyMac securities you may be entitled to compensation without payment of any out of pocket fees or costs through a c ...

NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of GSI Technology Inc. (NASDAQ: GSIT) resulting from allegations that GSI Technology may have issued materially misleading business information to the investing public. SO WHAT: If you purchased GSI Technology securities you may be entitled to compensation without payment of any out of pocket fees or costs through a cont ...

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged misleading statements regarding the efficacy of setrusumab, impacting investors who purchased stock between August 3, 2023, and December 26, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx made false statements about setrusumab's potential, specifically that while it increases bone density, this does not correlate with a decrease in fracture rates, contrary to management's claims [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by April 6, 2026, to represent the class in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc due to allegations of violations of federal securities laws related to misleading statements about the effects of setrusumab on patients with Osteogenesis Imperfecta [4]. Group 1: Legal Investigation - The law firm is encouraging Ultragenyx investors who suffered losses exceeding $50,000 to contact them for discussing legal options [1]. - A federal securities class action has been filed against Ultragenyx, with a deadline of April 6, 2026, for investors to seek the role of lead plaintiff [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against Ultragenyx - The complaint alleges that Ultragenyx and its executives created a false impression regarding the reliability of information on setrusumab's effects, while downplaying the risks associated with the Phase III Orbit study [4]. - It is claimed that Ultragenyx's optimism regarding the study's results was misplaced, as the data was based on Phase II results without a placebo control group, raising concerns about the validity of the findings [4]. Group 3: Participation and Whistleblower Information - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [5]. - The firm is also encouraging individuals with information regarding Ultragenyx's conduct, including whistleblowers and former employees, to come forward [6].

Core Insights - Coupang, Inc. experienced a significant drop in share price, falling over 13% due to a report of an additional 165,000 user data being leaked, compounding the previously reported breach affecting 33 million users [1][2] Company Developments - The interim CEO, Harold Rogers, is under investigation by South Korean authorities for potential perjury related to statements made about the data breach during a National Assembly hearing [2] - The investigation focuses on Rogers' claims that the cybersecurity incident was directed by the Korean government, which the government has denied [2] - Following the breach revelations, Coupang's share price has seen a severe decline since late November 2025 [2] Legal Actions - A securities class action lawsuit has been initiated to represent investors who acquired Coupang securities between May 7, 2025, and December 16, 2025, encouraging affected investors to report their losses [3][4] - The lawsuit alleges that Coupang misled investors by promoting "proactive security" measures while failing to detect a significant data breach for nearly six months, which affected 33.7 million accounts [4] - The breach was reportedly executed by a former employee using authentication keys that remained valid post-departure, leading to a $1.2 billion compensation plan and a CEO resignation, resulting in over $8 billion in market value loss [4] Company Statements - On December 29, 2025, Coupang filed a report with the SEC stating that its investigation was conducted under government direction, which may contradict earlier statements made by the interim CEO [5] - The firm Hagens Berman is leading the investigation into the claims and is encouraging whistleblowers with non-public information to come forward [6]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of PennyMac Financial Services, Inc. due to allegations of materially misleading business information issued by the company [1]. Financial Performance - On January 29, 2026, PennyMac reported its fourth quarter and full-year 2025 financial results, revealing a pretax income of $37.3 million for its servicing segment, a significant decrease from $157.4 million in the prior quarter and $87.3 million in the same quarter of 2024 [3]. - The report indicated that pretax income excluding valuation-related items was $47.8 million, down 70% from the previous quarter, primarily due to increased realization of mortgage servicing rights cash flows as lower mortgage rates led to higher prepayment activity [3]. Stock Market Reaction - Following the financial report, PennyMac's stock price dropped by $49.78 per share, or 33.3%, closing at $99.92 per share on January 30, 2026 [3]. Legal Action - Investors who purchased PennyMac securities may be entitled to compensation through a class action lawsuit being prepared by Rosen Law Firm, which operates on a contingency fee basis, meaning no out-of-pocket costs for investors [2]. - Interested investors can join the class action by submitting a form or contacting the law firm directly [2]. Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and being recognized for its success in the field [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Tandem Diabetes securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. - Rosen Law Firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Company Incident and Stock Impact - On August 7, 2025, Tandem Diabetes issued a press release regarding a voluntary medical device correction for select t:slim X2 insulin pumps, addressing a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of securities of Richtech Robotics Inc. for the period between January 27, 2026, and January 29, 2026, alleging false and misleading statements by the company [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Richtech Robotics falsely stated it had a collaborative relationship with Microsoft, which it did not have, leading to materially false and misleading statements about the company's business and prospects [5]. - Investors who purchased Richtech Robotics securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly. A lead plaintiff must move the court by April 3, 2026 [3][6]. - It is noted that no class has been certified yet, and investors can choose to remain absent or select their own counsel [7]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013, recovering hundreds of millions for investors [4].